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Introduction: External pneumatic compression devices (EPC) prevent deep venous thrombosis (DVT) by reducing lower
extremity venous stasis. Early studies suggested they also enhance fibrinolytic activity; however, in a recent study, EPC
had no effect on systemic fibrinolysis in patients undergoing abdominal surgery. The hypothesis of this study was that
EPCs enhance regional fibrinolysis in these subjects.
Methods: Forty-five patients (44 male, one female; mean age, 67 years) undergoing major abdominal surgery (35 bowel
procedures, 10 aortic reconstructions) were prospectively randomized to one of three groups for DVT prophylaxis:
subcutaneous heparin injections (HEP), thigh-length sequential EPC devices (EPC), or both (HEPEPC). Prophylaxis
was begun immediately before surgical incision and continued until postoperative day 5 or patient discharge. Venous
blood samples were collected from the common femoral vein for measurement of regional fibrinolysis after induction of
anesthesia but before initiation of prophylaxis, and on postoperative days 1, 3, and 5. A baseline sample was collected the
day before surgery. Fibrinolysis was quantified with measurement of the activities of tissue plasminogen activator (tPA;
the activator of fibrinolysis) and its inhibitor plasminogen activator inhibitor-1 (PAI-1) with amidolytic technique.
Results: tPA activity in all groups was normal at baseline; baseline PAI-1 activity was elevated. Within each prophylaxis
group, no significant changes occurred in either tPA or PAI-1 activities after induction of anesthesia or after surgery
compared with before surgery (P > .05, analysis of variance with repeated measures). No changes occurred between
postoperative samples and after anesthesia within each group. No significant enhancement of fibrinolysis, manifested as
either increased tPA activity or decreased PAI-1 activity, occurred in either EPC group compared with the HEP group at
any time point (P > .05, analysis of variance with repeated measures). No differences were noted when surgery was
performed for malignant disease versus nonmalignant disease.
Conclusion: In this study, enhanced regional fibrinolysis in the lower extremities could not be detected with the use of
EPCs, as measured with tPA and PAI-1 activity in common femoral venous blood samples. EPC devices do not appear to
prevent DVT with fibrinolytic enhancement; effective and safe prophylaxis is provided only when the devices are used in
a manner that reduces lower extremity venous stasis. (J Vasc Surg 2002;36:953-8.)
The efficacy of external pneumatic compression (EPC)
devices in prevention of lower extremity deep venous
thrombosis (DVT) is well established. When used properly,
these devices reduce the incidence of lower extremity DVT
to that found with low-dose anticoagulation therapy.1-9
The primary mechanism by which EPC devices prevent
DVT is reduction of lower extremity venous stasis. This has
been shown as increased venous flow velocities in major
lower extremity veins obtained with duplex ultrasound
scan8-12 and with increased lower extremity venous flow
shown with plethysmography.6
External pneumatic compression devices are also be-
lieved to enhance endogenous fibrinolysis, the system by
which the body lyses excess or inappropriately formed
thrombus.13 This belief originated from studies in which
tourniquet-induced compression of arm veins resulted in
increased plasma fibrinolytic activity. It was presumed that
venous compression resulted in the increased synthesis or
secretion of profibrinolytic factors from the venous endo-
thelium.14,15 Because EPC devices also compress endothe-
lium, investigators concluded that they must also increase
fibrinolysis. Early clinical studies showed that EPC devices
increased fibrinolysis in healthy volunteers and surgical
patients and prevented the reduction in fibrinolysis (“fi-
brinolytic shutdown”) that normally follows surgery.2,16-19
However, the techniques available to measure fibrino-
lytic activity at the time these studies were published were
crude and nonspecific because of the lack of understanding
of the enzymatic mechanism of fibrinolysis. Moreover, it
was not understood that numerous variables, including
age, time of day, and the presence of diseases such as
atherosclerosis and cancer,20,21 affect fibrinolysis, and
therefore, no attempts were made to control these vari-
ables. Closer inspection of the results of many of the studies
shows inconsistencies and conflicting data.
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More recent studies in which the rate-limiting enzymes
of fibrinolysis are measured have generally not confirmed
the original findings.22-26 A study conducted in our labo-
ratory found no effect of EPC devices on systemic fibrino-
lytic activity, measured from antecubital venous samples.27
However, any increase in fibrinolysis produced by EPC
might not be measurable in the systemic circulation be-
cause of dilution and hepatic clearance of fibrinolytic fac-
tors. The hypothesis of this study was therefore that EPC
devices enhance regional fibrinolytic activity in the lower
extremity to which they are applied.
METHODS
Forty-five patients (44 males, one female; mean age, 67
years) undergoing major abdominal surgery were random-
ized to one of three groups for DVT prophylaxis: 1, unfrac-
tionated heparin injections given subcutaneously at a dose
of 5000 units twice a day (HEP); 2, thigh-length sequential
pneumatic compression device (EPC; Kendall Health Care,
Manchester, Mss); or 3, combination of both methods
(HEPEPC). The surgical procedures that were per-
formed are listed in the Table; these included 10 abdominal
aortic aneurysm repairs, 25 resections for malignant dis-
ease, and 10 miscellaneous laparotomies (nine bowel resec-
tions/lysis of adhesions, one splenectomy). Patients under-
going aortic reconstruction were given systemic doses of
heparin during the surgical procedure, which were reversed
at the end of the procedure with protamine. The protocol
was approved by the Institutional Review Board, and all
subjects gave informed consent before participation.
A venous duplex ultrasound scan was performed before
enrollment in the study to exclude the presence of preex-
isting venous disease, and a second ultrasound scan was
performed on postoperative day 5 or before discharge to
exclude the development of DVT. Those patients with a
history or ultrasound scan evidence of venous thromboem-
bolic disease, or a requirement for systemic anticoagulation
therapy, were excluded. Ultrasound scans were performed
from the confluence of the tibial veins to the iliac veins; calf
veins were not routinely scanned because calf vein DVT
were not considered clinically significant. The criteria for a
positive ultrasound scan have been previously reported.28
DVT prophylaxis was initiated in the operating room after
induction of anesthesia and continued until postoperative
day 5 or discharge. In the event that a postoperative ultra-
sound scan identified a proximal DVT, the patient was
withdrawn from the study and treated for DVT with stan-
dard methods. The decision for method of treatment was
left to the discretion of the patient’s regular physician.
Fibrinolysis was quantified with measurement of the
biologic activities of tissue plasminogen activator (tPA; the
activator of fibrinolysis) and its inhibitor plasminogen acti-
vator inhibitor-1 (PAI-1). For measurement of regional
fibrinolytic activity, samples were collected from the com-
mon femoral vein on the day before surgery, after induction
of anesthesia but before initiation of prophylaxis, and on
postoperative days 1, 3, and 5. All samples were collected
between 7:00 am and 11:00 am to eliminate the known
diurnal variations in fibrinolysis.29 All subjects in the EPC
and EPCHEP groups wore EPC devices on both lower
extremities, and all sampling was performed from the same
extremity in each patient. The choice of extremity was
determined randomly. To ensure maximum compliance
with the study protocol, a study coordinator monitored the
devices twice daily to ensure that they remained on the
patient. The nursing staff in the intensive care units and on
the wards were inserviced regarding the study protocol and
the need for the patients to wear the devices at all times. No
attempts were made to control ambulation in any of the
subjects; it was assumed this would be similar among the
groups given the similarity of the surgical procedures.
For determination of tPA activity, blood was first col-
lected into 130 mmol/L sodium citrate anticoagulant (9:1
volume) and immediately acidified with addition of 0.5
mmol/L sodium acetate, pH 4.2 (2:1 volume), to prevent
the ongoing in vitro inactivation of tPA by complex forma-
tion with PAI-1.30 Samples for measurement of PAI-1
activity were collected into a 5-mL syringe containing
modified Files solution (1 mL acid citrate dextrose solu-
tion, 80 L acetylsalicylic acid solution, 10 L prostaglan-
din E1) to minimize in vitro platelet activation (final dilu-
tion, 1:5).31 Samples were maintained at 4° C until
centrifugation at 10,000g for 20 minutes. Platelet-poor
plasma was stored at 80° C until assays were performed.
Patient characteristics
HEP EPC HEPEPC P value
Number of subjects 16 15 13
Age (y; mean  standard error of mean) 66.6  1.8 67.1  2.0 67.5  2.2 .96
Atherosclerosis* 11 (68.8%) 10 (66.7%) 9 (64.3%) .99
Surgical procedures .50
Aortic reconstructions 3 (18.8%) 5 (33.3%) 2 (14.3%)
Abdominal cancer procedures 11 (68.8%) 6 (40.0%) 8 (57.1%)
Colectomies 10 5 7
Esophagectomies 0 1 1
Whipple procedures 1 0 0
Miscellaneous laparotomies 2 (12.5%) 4 (26.7%) 4 (28.6%)
*Atherosclerosis was defined as patient-reported history of coronary artery disease (CAD), myocardial infarction, or peripheral arterial occlusive disease,
electrocardiographic evidence of CAD, or revascularization for CAD, peripheral arterial occlusive disease, or carotid artery disease.
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The activity levels of tPA and PAI-1 were measured
with amidolytic methodology.32 Assays were performed in
duplicate, and interassay variability was less than 5%. tPA
activity was expressed in international units (IU/mL) as-
sessed against the Second International Standard for tPA
from the National Institute for Biological Standards and
Control.33 PAI-1 activity was expressed in arbitrary units
(AU/mL); 1 arbitrary unit of inhibitor equals the amount
that inhibits 1 international unit of tPA/mL plasma.34
Values for tPA activity were combined for subjects in
each group at each time point. Values for PAI-1 activity
were treated similarly. All data were expressed as the
mean  standard error of the mean. The activity levels of
tPA and PAI-1 were analyzed with analysis of variance for a
two-factor experiment with repeated measures on one fac-
tor (time). The two factors were patient group (HEP, EPC,
HEPEPC) and time (five time points: before surgery,
after anesthesia, and postoperative days 1, 3, and 5). Ages
of the three patient groups were compared with one-way
analysis of variance. Association between the prevalence of
atherosclerosis and patient groups, and between surgical
procedures and patient groups, was assessed with the Fisher
exact test. All tests were assessed at the .05 level of signifi-
cance.
RESULTS
Subjects and procedures. Forty-five subjects partici-
pated in this study and were divided equally among the
three treatment groups. Mean age, prevalence of athero-
sclerosis, and frequencies of surgical procedures for each
group are summarized in the Table. There were no signif-
icant differences in age among the three groups (P  .96).
The prevalence of atherosclerosis was similar among the
three groups (P  .99). Association between surgical pro-
cedures and patient groups was not significant (frequencies
of each of the three major types of procedures were similar
among the groups; P  .50). No subject had signs or
symptoms of venous thromboembolism develop during the
study. Venous duplex ultrasound scans were performed on
81% of the subjects after surgery; no proximal DVT were
identified.
tPA activity. tPA activities in the three groups were
normal before surgery (1.16  0.24 IU/mL to 1.63 
0.31 IU/mL; Fig 1). tPA activities among the three patient
groups were not statistically different at any time point
(group main effect, P .83; group by time interaction, p
.29). In addition, the difference between any two time
points was not statistically different in any of the groups
(time main effect, P  .29).
PAI-1 activity. Mean PAI-1 activities of the three
groups (19.2 3.4 AU/mL to 24.4 1.7 AU/mL; Fig 2)
were elevated compared with age-matched and gender-
matched healthy subjects20 at baseline. PAI-1 activities
among the three groups were not statistically different at
any time point (group main effect, P  .41; group by time
interaction, P  .87). In addition, the difference between
any two time points was not statistically different in any of
the patient groups (time main effect, P  .57).
Effect of malignant disease on fibrinolysis and EPC
devices. Fifty-seven percent of subjects (25 of 45) in this
study underwent laparotomy for treatment of malignant
disease. Because of this, and because of the known influ-
ence of malignant disease on fibrinolysis,35,36 the data were
reanalyzed, taking into account of the presence or absence
of malignant disease. Subjects who underwent abdominal
cancer procedures were similarly distributed among the
three groups (P  .50; Table). There was higher regional
tPA activity in subjects without malignant disease com-
pared with those with malignant disease (1.76  0.14
IU/mL without malignant disease; 1.10  0.23 IU/ml
with malignant disease; P .02). There were no significant
differences in PAI-1 activities between the subjects with
malignant disease and those without (19.6  1.9 AU/mL
without malignant disease; 25.6  1.8 AU/mL with ma-
lignant disease; P  .06).
DISCUSSION
In 1972, Hills et al37 showed that application of a
pneumatic compression device to the legs of patients un-
dergoing surgery for nonmalignant disease prevented the
development of postoperative DVT, and in subjects with
malignant disease, there was no benefit. This finding led
Allenby et al14 to speculate that the coagulation system in
the two groups might be different and that the EPC device
might be affecting it. At the same time, venous occlusion
with a tourniquet on the arm was shown to increase fibri-
nolysis in the veins distal to the tourniquet.38 If tourniquet
compression produced increased fibrinolysis, it seemed log-
ical that intermittent compression would also increase fibri-
nolysis. Until this time, EPC devices had been shown to
increase lower extremity venous flow,39,40 and this was
Fig 1. tPA activity (IU/mL) in each group.
Fig 2. PAI-1 activity (AU/mL) in each group.
JOURNAL OF VASCULAR SURGERY
Volume 36, Number 5 Killewich et al 955
thought to be the mechanism by which they prevented the
development of DVT.
Allenby et al14 measured euglobulin clot lysis times
(ECLT; a crude measure of global fibrinolysis) in surgical
patients treated with EPC devices. Subjects undergoing
surgery for nonmalignant disease had decreased ECLTs
(increased fibrinolysis), whereas those with malignant dis-
ease and control subjects not treated with pneumatic com-
pression had increased ECLT. Allenby et al14 proposed that
enhancement of fibrinolysis by increased secretion of fi-
brinolytic factors from vein walls was the primary mecha-
nism by which EPC devices prevent DVT and, because the
effect appeared to be systemic, suggested that in the future
it might be possible to provide DVT prophylaxis in the legs
by application of these devices to the arms. A later paper
provided evidence that EPC applied to the arms resulted in
increased fibrinolytic activity measured in the common
femoral vein.15
Soon thereafter, Salzman, McManama, and Shapiro17
showed that EPC protected against postoperative fibrino-
lytic shutdown in patients undergoing neurosurgical pro-
cedures, and Inada et al18 found similar results in patients
undergoing surgical procedures for malignant disease. Ca-
prini et al2 showed reduced postoperative fibrinolytic shut-
down with EPC devices in patients undergoing orthopedic
or neurosurgical procedures, although in patients undergo-
ing abdominal surgery the devices had no effect.
None of these early studies, however, used techniques
in which the specific enzymatic components of fibrinolysis
were measured, and many variables (time of day, age,
atherosclerosis) now known to affect fibrinolytic activity
were not controlled. The results must therefore be viewed
with caution. Tarnay et al16 did measure fibrinolytic activity
in the arms and legs (femoral vein sampling) of healthy
volunteers in a more controlled study and found that
fibrinolytic activity in the legs increased by 22% after 1 hour
of pumping. Systemic activity measured from the arms,
however, increased only 6% and barely achieved statistical
significance.
In our laboratory, studies were performed on both
healthy volunteers and surgical patients, with measurement
of tPA and PAI-1 activities on antecubital venous samples
to quantify systemic fibrinolysis. We were unable to show
an effect of EPC devices on systemic fibrinolysis in either
group. In healthy volunteer subjects, neither a thigh-length
sequential, calf-length sequential, or arteriovenous foot
pump produced statistically significant increases in tPA
activity or decreases in PAI-1 activity during a 3-hour
pumping period (unpublished data). In subjects undergo-
ing abdominal surgery, EPC devices produced no changes
in systemic tPA or PAI-1 and did not prevent postoperative
fibrinolytic shutdown.27
It is possible that EPC devices produce an increase in
tPA secretion from lower extremity veins when applied
there, but the effect is not measurable from the systemic
circulation because of dilution and the hepatic clearance of
tPA.41 In this study, we measured fibrinolytic activity on
venous samples collected from the common femoral veins
of legs pumped with a thigh-length sequential compression
device, presuming that this would provide the most direct
method of assessing the effects of EPC devices on secretion
of fibrinolytic factors from vein wall endothelium. How-
ever, we were again unable to show any effect of the EPC
device on postoperative fibrinolysis, manifested as either
increased tPA activity or decreased PAI-1 activity. Neither
the presence of atherosclerosis or malignant disease affected
these results.
The results of other recent studies addressing the ef-
fects of EPC devices on fibrinolysis have also been conflict-
ing. Comerota et al25 studied systemic (antecubital) fi-
brinolytic activity in healthy volunteers treated with five
different pneumatic compression devices. They found small
(18%) but significant decreases in PAI-1 activity and in-
creases in tPA activity (4%) with all devices. Jacobs et al
showed decreased PAI-1 antigen levels in the inferior vena
cava of healthy volunteers after a 4-hour compression pe-
riod, but no changes occurred after a second period of
compression.22 Christen et al24 found no changes in either
tPA or PAI-1 antigen levels measured from the antecubital
vein in healthy volunteers after pumping with a sequential
leg device and a foot pump. Kosir et al26 evaluated tPA and
PAI-1 antigen levels in patients undergoing general surgi-
cal procedures treated with either heparin or EPC devices.
They found increases in both measurements in patients
treated with both methods of DVT prophylaxis, making it
difficult to draw conclusions regarding the effect of EPC on
fibrinolysis.
Review of the original suppositions on which the the-
ory of enhanced fibrinolysis with EPC is based raises addi-
tional questions regarding its validity. Placement of a tour-
niquet on the forearm for 15 to 30 minutes was observed to
produce elevated levels of tPA in the arm distal to the
tourniquet, and this was presumed to result from increased
endothelial secretion.42 However, recent data and com-
puter modeling of the kinetics of tPA metabolism show that
the increased levels of tPA associated with venous occlusion
result from trapping of tPA distal to the tourniquet and that
the basal rate of secretion of tPA remains unchanged.41-43
Because EPC devices compress intermittently, no trapping
of tPA occurs. Early studies suggested that increased blood
flow resulting in higher than normal shear stress values
might also be associated with increased secretion of tPA
from venous endothelium. However, it was later shown
that this only occurs at shear stress rates associated with
arterial flow.44,45 Evidence that compression of the venous
endothelium results in changes in levels of PAI-1 is also
lacking. Recent data show that PAI-1 secretion from ve-
nous endothelium is low and not physiologically important
and that PAI-1 secretion occurs primarily from the liv-
er.41,46,47 Studies involving catecholamine injection have
shown increases in forearm tPA activity but no changes in
PAI-1.47,48 When all of the evidence is considered, en-
hancement of either regional or systemic fibrinolysis from
intermittent compression seems unlikely.
In this study, baseline tPA activity was within the
normal range for subjects of this age group, but baseline
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PAI-1 activity was markedly elevated. The most likely ex-
planation for this elevation is the high incidence rate of
atherosclerotic disease in the study population. Seventy-five
percent of the subjects had evidence of atherosclerosis in
the coronary, carotid, or peripheral circulations. There is
considerable evidence that atherosclerosis is associated with
elevations of PAI-1 activity.20,21
The presence of malignant disease is also known to
affect endogenous fibrinolysis.35,36 Malignant disease has
been associated with elevations of urokinase plasminogen
activator,36 thrombin-antithrombin complex, and pro-
thrombin fragment 12.35 In a previous study, we found a
significant correlation between the presence of malignant
disease and tPA activity,27 similar to that found here. Most
importantly, EPC devices did not produce a greater in-
crease in fibrinolysis in subjects with nonmalignant disease
compared with those with malignant disease. The presence
of malignant disease resulting in impaired fibrinolysis did
not “mask” any effect of EPC devices on endogenous
fibrinolysis in this study.
In conclusion, EPC devices do not increase endoge-
nous fibrinolytic activity either systemically or in the ex-
tremity to which they are applied, at least through increased
tPA activity or decreased PAI-1 activity. It is possible that
they produce an anticoagulant state through a different
mechanism. However, until more information regarding
these alternative mechanisms of anticoagulation is pro-
vided, effective and safe DVT prophylaxis with EPC devices
can be assured only in the setting of enhanced venous flow
velocities.
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